| Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. | |
| | |
MedLine Citation:
|
PMID: 19450721 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Blood pressure (BP) is a continuous risk factor for ischemic and atherosclerotic events such as stroke and ischemic heart disease, and controlling BP is a well-established component of any cardiovascular or cerebrovascular risk reduction regimen. In most patients, > or =2 medications with different mechanisms of action will be necessary to reach recommended BP goals. The neuroendocrine effects of the renin-angiotensin-aldosterone-system (RAAS) have proven to be excellent therapeutic targets for BP lowering. A number of antiatherosclerotic effects have been attributed to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in addition to their antihypertensive effects. Because they have complementary actions on the RAAS, combination therapy with these agents has become the focus of recent clinical trials. This review describes the clinical data assessing the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers individually and in combination in reducing the risk of stroke and ischemic heart disease. |
| | |
Authors:
|
Vasilios Papademetriou |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: American heart journal Volume: 157 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-19 Completed Date: 2009-11-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: S24-30 Citation Subset: AIM; IM |
Affiliation:
|
Department of Veterans Affairs and Georgetown University Medical Centers, Washington, DC 20422, USA. papavip@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use* Blood Pressure Determination Cardiovascular Diseases / etiology, mortality, prevention & control* Coronary Artery Disease / etiology, mortality, prevention & control Drug Therapy, Combination Female Humans Hypertension / complications, diagnosis, drug therapy* Male Myocardial Ischemia / etiology, mortality, prevention & control Prognosis Randomized Controlled Trials as Topic Receptors, Angiotensin / antagonists & inhibitors*, therapeutic use Renin-Angiotensin System / drug effects*, physiology Risk Assessment Severity of Illness Index Stroke / etiology, mortality, prevention & control* Survival Rate Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Receptors, Angiotensin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure seco...
Next Document: Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers ...